Table 1.
Days afer immunization | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
30 | 32 | 34 | 36 | 38 | 40 | 42 | 44 | 46 | 48 | 50 | |
CFA | 0/20 | 0/20 | 0/20** | 0/20** | 0/20*** | 0/20*** | 0/20*** | 0/20*** | 0/20*** | 0/20*** | 0/20*** |
EAMG | 1/20 | 3/20 | 7/20 | 7/20 | 12/20 | 13/20 | 17/20 | 19/20 | 19/20 | 19/20 | 19/20 |
Anti-IL-9 Abs, Low dose | 0/19 | 4/19 | 4/19 | 7/19 | 10/19 | 11/19 | 14/19 | 15/19 | 16/19 | 16/19 | 16/19 |
Anti-IL-9 Abs, High dose | 0/19 | 1/19 | 2/19 | 3/19 | 4/19* | 5/19* | 7/19** | 7/19*** | 8/19*** | 8/19*** | 10/19** |
Abbreviations: CFA, complete Freund's adjuvant; EAMG, experimental autoimmune myasthenia gravis; IL-9 Abs, interleukin-9 antibodies.
Incidences were compared with the experimental autoimmune myasthenia gravis (EAMG) group.
Statistical comparisons among the clinical incidences were made by Fisher's exact test.
P < 0.05,
P < 0.01,
P < 0.001.